Supplementary Material

The Economic Benefit of Remission for Patients With Rheumatoid Arthritis

Jeffrey R. Curtis, MD, MS, MPH; Kathleen M. Fox, PhD; Fenglong Xie, PhD; Yujie Su, MS; David Collier, MD; Cassie Clinton, MSHA; Hafiz Okoosi, MS, RPh

1University of Alabama at Birmingham, Birmingham, AL, USA
2Amgen Inc., Thousand Oaks, CA, USA
3Gilead Sciences, Inc., Foster City, CA, USA

*Corresponding author:
Kathleen M. Fox, PhD
Amgen Inc., Thousand Oaks, CA, USA
Email: kathyfox@strategichealth.biz
Phone: +1 443-690-2198
ORCID: 0000-0003-2100-277X
**Supplementary Table 1: Overall proportion of patients who change disease activity from baseline to end of follow-up**

| Follow-up Stage, Patients | Low Disease Activity | Moderate Disease Activity | High Disease Activity |
|---------------------------|----------------------|--------------------------|-----------------------|
| Remission                 | 308 (63.5)           | 107 (11.1)               | 16 (2.5)              | 9 (3.5)               |
| Low disease activity      | 123 (25.4)           | 643 (66.8)               | 145 (22.9)            | 25 (9.6)              |
| Moderate disease activity | 46 (9.5)             | 170 (17.7)               | 390 (61.7)            | 70 (26.9)             |
| High disease activity     | 8 (1.6)              | 42 (4.4)                 | 81 (12.8)             | 156 (60.0)            |
Supplementary Table 2: Proportion of patients who change disease activity from index to end of follow-up by RA therapy group

| Index RA Therapy | csDMARDs (N = 1,219) | TNFis (N = 476) | Non-TNFis (N = 282) | tsDMARDs (N = 88) | None* (N = 274) |
|------------------|----------------------|-----------------|---------------------|-------------------|-----------------|
| Stage change, n (%) |                      |                 |                     |                   |                 |
| R-R              | 175 (14.4)           | 59 (12.4)       | 39 (13.8)           | 10 (11.4)         | 25 (9.1)       |
| R-L              | 55 (4.5)             | 24 (5.0)        | 6 (2.1)             | 7 (8.0)           | 15 (5.5)       |
| R-M              | 11 (0.9)             | 3 (0.6)         | 2 (0.7)             | 0 (0.0)           | 0 (0.0)        |
| R-H              | 3 (0.2)              | 4 (0.8)         | 1 (0.4)             | 0 (0.0)           | 1 (0.4)        |
| L-R              | 68 (5.6)             | 24 (5.0)        | 17 (6.0)            | 1 (1.1)           | 13 (4.7)       |
| L-L              | 351 (28.8)           | 129 (27.1)      | 60 (21.3)           | 19 (21.6)         | 84 (30.7)      |
| L-M              | 61 (5.0)             | 40 (8.4)        | 22 (7.8)            | 5 (5.7)           | 17 (6.2)       |
| L-H              | 7 (0.6)              | 8 (1.7)         | 9 (3.2)             | 1 (1.1)           | 0 (0.0)        |
| M-R              | 23 (1.9)             | 10 (2.1)        | 8 (2.8)             | 0 (0.0)           | 5 (1.8)        |
| M-L              | 85 (7.0)             | 38 (8.0)        | 25 (8.9)            | 4 (4.5)           | 18 (6.6)       |
| M-M              | 195 (16.0)           | 78 (16.4)       | 50 (17.7)           | 23 (26.1)         | 44 (16.1)      |
| M-H              | 34 (2.8)             | 10 (2.1)        | 10 (3.5)            | 5 (5.7)           | 11 (4.0)       |
| H-R              | 5 (0.4)              | 2 (0.4)         | 0 (0.0)             | 1 (1.1)           | 0 (0.0)        |
| H-L              | 24 (2.0)             | 7 (1.5)         | 3 (1.1)             | 0 (0.0)           | 8 (2.9)        |
| H-M              | 48 (3.9)             | 12 (2.5)        | 10 (3.5)            | 3 (3.4)           | 8 (2.9)        |
| H-H              | 74 (6.1)             | 28 (5.9)        | 20 (7.1)            | 9 (10.2)          | 25 (9.1)       |

csDMARD = conventional synthetic disease-modifying antirheumatic drug; H = high disease activity; L = low disease activity; M = moderate disease activity; R = remission; RA = rheumatoid arthritis; TNFi = tumor necrosis factor inhibitor; tsDMARD = targeted synthetic disease-modifying antirheumatic drug. *None = no DMARDs of any type in the baseline period.
Supplementary Figure 1: Study design schema

Index date: The calendar date at which the patient met all inclusion/exclusion criteria and is also the date at which follow-up begins.

To be eligible, patients must have ≥2 rheumatologist visits with a valid CDAI measure occurring within 18 months of one another, of which one had to occur within 18 months prior to index date.

CDAI = Clinical Disease Activity Index; RA = rheumatoid arthritis; UHC = United HealthCare
Supplementary Figure 2: Mean annual costs by disease activity stage during follow-up stratified by cost type

Pharmacy total = pharmacy + intravenous infusion